Advanced bladder cancer: Status of first-line chemotherapy and the search for active agents in the second-line setting

Cancer

Volumn 113, Issue 6, 2008, Pages 1284-1293

  Gallagher, David J ^a   Milowsky, Matthew I ^a,b   Bajorin, Dean F ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bladder cancer; Second line; Transitional cell carcinoma of the urothelium; Urothelial carcinoma

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; IXABEPILONE; LAPATINIB; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PIRITREXIM; SORAFENIB; SUNITINIB; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINFLUNINE;

ADVANCED CANCER; ANEMIA; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTINUOUS INFUSION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CANCER; KIDNEY DYSFUNCTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSORY NEUROPATHY; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; URINARY BLADDER NEOPLASMS;

EID: 53149143875     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23692     Document Type: Review

References (76)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Cookson MS, Herr W, Zhang ZF, et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997;158:62-67.
3. Stein JR Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19:666-675.
4. Bladder Cancer Guidelines. Clinical Practice Guidelines in Oncology (version 2.0). J Natt Cancer Netw. 2007:NS-l.
5. Babaian RJ, Johnson DE, Llamas I., Ayala AG, et al. Metastases from transitional cell carcinoma of urinary bladder. Urology. 1980;16:142-144.
6. Yagoda A. Progress in treatment of advanced urothelial tract tumors. J Clin Oncol. 1985;3:1448-1450.
7. Whitmore W Jr, Yagoda A. Chemotherapy in the management of bladder tumours. Drugs. 1989;38:301-312.
8. Stoter G, Splinter JH, Child IA, et al. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol. 1987;137:663-667.
9. Harker WG, Meyers FJ, Freiha FS, et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol. 1985;3:1463-1470.
10. Stemberg CN, Yagoda A, Schar HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985;133:403-407.
11. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992:10:1066-1073.
12. Logothetis CJ, Dexius FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8:1050-1055.
13. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564-2569.
14. Stemberg CN, de Malder P, Schomagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19: 2638-2646.
15. Stemberg CN, de Malder P Schomagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006; 42:50-54.
16. Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:220-228.
17. von der Maase H, Hansen SU, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077.
18. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602-4608.
19. Dogliotti L, Carteni G, Siena S, et al. Gamatabine plus cisplatin versus gamatabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase II trial. Eur Urol. 2007;52:134-141.
20. Nogue-Aliguer M, Carls J, Aerivi A, et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer. 2003;97:2180-2186.
21. Olivares J, Hyman W, Senger N, et al. A phase II trial of gemcitabine and carboplatin (GC) in patients with transitional cell carcinoma of the urinary tract (TCC). Proc Am Soc Clin Oncol. 2004;22:14S. Abstract 4590.
22. Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer. 2004;100:1639-1645.
23. Bellmunt J, Abanell G, Gallego OS, et al. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for chemotherapy. Cancer. 1992;70:1974-1979.
24. Boccardo F, Pace M, Guameri D, et al. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial. Cancer. 1994;73:1932-1936.
25. Bajorin DF, McCaffrey JA, Dodd PM. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating 2 dosing schedules. Cancer. 2000;88:1671-1678.
26. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001;19:2527-2533.
27. de Wit R, European Organization for Research and Treatment. Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer. 2003; 97(8 suppl):2120-2126.
28. Bellmunt J et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. Proc Am Soc Clin Oncol. 2007;25:18S.
29. Bajorin DF, Dodd PM, Mazundar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173-3181.
30. Bellmunt J, Abanell J, Pez-Anes L, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer. 2002;95:751-757.
31. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer. 2006; 94:1395-1401.
32. Vaishampayan UN, Faulkner JR, Small EJ, et al. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer. 2005;104:1627-1632.
33. Tournigand C, Andre T, Achill E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22:229-237.
34. Witte RS, Mansla J, Burch PA, Kuzel T, Weinshel BL, Loehrer PJ. Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial. Invest New Drugs. 1998;16:191-195.
35. Dodd PM, McCaffrey JA, Miazumdar M. Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma. Invest New Drugs. 2000;18:247-251.
36. Roth BJ, Manola J, Dreicer R. Ciraham I), Wilding (G, Faster n (Cooperative Oncology (iroup. I'iritrexim in advanced, refractor)' carcinoma of the urothelium (F3896); a phase II trial of the Hastern Cooperative Oncology (Group. Invest New Drugs. 2002;20:425-429.
37. Winquist F, Moore MJ, Chi KN, et al. A multinomiul Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol. 2005;23:143-149.
38. Witte RS, Hison P, Bond B, et al. Hastern Cooperative Oncology Croup phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol. 1997:15:589-593.
39. de Wit R, Kruit WH, Stoter G, de Boar M, Kerger J, Verweij J. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapypretreated patients. Br J Cancer. 1998;78:1342-1345.
40. McCaffrey JA, Hiller S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15:1853-1857.
41. Vaughn DJ, Broome CM, Hussain M, Gulteil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 2002;20:937-940.
42. Dreicer R, Li S, Manola J, Haas NB, Roth BJ, Wilding G. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer. 2007;110:759-763.
43. Castagneto B, Zai S, Marenco I), et al. Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment. Oncology. 2004;67:27-32.
44. Stadler WM, Kuzel TM, Rashavan J, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15: 3394-3398.
45. Moore MJ, Tannock IF, Eanst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997; 15:3441-3445.
46. Gebbia V, Testa A, Borsellino N, et al. Single agent 2′,2′- difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter. 1999;150:11-15.
47. Pollera CF, Ceribelli A, Grecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol. 1994;5:182-184.
48. Lorusso V, Pollera CF, Antoni M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer. 1998;34:1208-1212.
49. Albers P, Siener R, Haatlein M, et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. On kologie. 2002;25:47-52.
50. von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther. 2003;3:11-19.
51. Paz-Ares I. et al. A phase II study of the multi-targeted antifolate, MIA (LY231514), in patients with advanced transitional cell carcinoma (TCC) of the bladder. Presented at the ASCO Annual Meeting, 1998. Proc Am Soc Clin Oncol. 1998. Abstract 1307.
52. Sweeney CJ. Koth BJ. Kabbinover FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24:3451-3457.
53. Galsky MD. Mironov S, Insonos M, Scattergood I, Boyle MG, Bogorin I)F Phase II trial of pemetrexed as secondline therapy in patients with metastatic urothelial carcinoma. Invest New Drugs. 2006;25:265-270.
54. Kruczynski A, Colpaeat F, Tarayre JP, Maillar P, F'ahy J. Hill B. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol. 1998;41:437-447.
55. Bonfil RD, Russo DM, Binda MM, Delgado FM, Vincelli M. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol. 2002;7:159-166.
56. Petrylak D et al. Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU). FCCO Annual Meeting Proceedings. Barcelona, Spain. September 23-27, 2007.
57. Fechner G, Siener R, Reimann M, et al. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract. 2006;60:27-31.
58. Sternberg CN, Caldoro F, Pizzocero G, Schevetger S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001;92:2993-2998.
59. Latif Z, Walters AD, Dunn I, Gngor K, Underwood MG, Bartlet JM. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer. 2004; 40:56-63.
60. Hussain M, MacVicar GR, Petrylak DP, et al. Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced HHR2-positive urothelial carcinoma: results of a multi-center Phase II NCI trial. Proc Am Soc Clin Oncol. 2005;23:16S. Abstract 4507.
61. Philips G et al. Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): analysis of the second cohort of CALGB 90102. Proc Am Soc Clin Oncol. 2006;24:18S. Abstract 4578.
62. Gomez-Abuin G, Winquist F, Stadler WM, et al. A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Flospital and University of Chicago phase II consortia. Invest New Drugs. 2007;25:181-185.
63. Wulfing C et al. A single arm, multicenter, open label, ph II study of lapatinib as 21. treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Proc Am Soc Clin Oncol. 2005;23:16S. Abstract 4594.
64. Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 1995;87:1603-1612.
65. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997;57: 5281-5285.
66. Bernardini S, Fauconnet S, Chabannes E, Henry PC, Adess CI, Bittard H. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol. 2001;166:1275-1279.
67. Gallagher DJ, Milowsky MI, Gerst S, et al. Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC). Proc Am Soc Clin Oncol. 2007; 25. Abstract 5080.
68. Bellmunt J, Mellado B, et al. Phase II study of sunitinib as first line treatment in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy. Proc Am Soc Clin Oncol (Genitourinary Symposium). 2008. Abstract 291.
69. Canes D et al. Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo. Int J Cancer. 2005;113:841-848.
70. Motzer RJ et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24.
71. Kelloff GJ et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;l 1:2785-2808.
72. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Bur J Cancer. 2006;42:1031-1039.
73. Choi H et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004;183:1619-1628.
74. Kelloff GJ et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res. 2005;11:7967-7985.
75. Moore MJ, Winquist E. Vohes EE, et al. Phase II study of oxaliplatin in patients with operable, locally advanced or metastatic transitional cell carcinoma of the urothelial tract who have received prior chemotherapy. Proc Am Soc Clin Oncol. 2003:22. Abstract 1638.
76. Lorusso V, Pollera CF, Antini M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer. 1998;34:1208-1212.